Thymalfasin for Chronic Hepatitis B: Clinical Evidence Review

Thymalfasin (thymosin alpha-1) demonstrated durable sustained response rates in chronic hepatitis B with excellent tolerability, supporting its use as an immune-based HBV therapy alternative to interferon.

Liaw, Yun-Fan·Journal of gastroenterology and hepatology·2004·Moderate EvidenceReview
RPEP-00941ReviewModerate Evidence2004RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Thymalfasin achieved sustained HBV virological response with increasing durability over follow-up and minimal side effects, positioning it as a well-tolerated immune-based alternative for chronic hepatitis B treatment.

Key Numbers

How They Did This

review study on thymosin-alpha-1, infection.

Why This Research Matters

Relevant for thymosin-alpha-1, infection, immune-function, clinical-trials.

The Bigger Picture

Advances peptide therapeutics research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Thymalfasin achieved sustained HBV virological response with increasing durability over follow-up and minimal side effects, positioning it as a well-t
Evidence Grade:
moderate evidence.
Study Age:
Published in 2004.
Original Title:
Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
Published In:
Journal of gastroenterology and hepatology, 19(12), S73-5 (2004)
Authors:
Liaw, Yun-Fan(2)
Database ID:
RPEP-00941

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Thymalfasin for Chronic Hepatitis B: Clinical Evidence Review

What was found?

Thymalfasin (thymosin alpha-1) demonstrated durable sustained response rates in chronic hepatitis B with excellent tolerability, supporting its use as an immune-based HBV therapy alternative to interferon.

Read More on RethinkPeptides

Cite This Study

RPEP-00941·https://rethinkpeptides.com/research/RPEP-00941

APA

Liaw, Yun-Fan. (2004). Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.. Journal of gastroenterology and hepatology, 19(12), S73-5.

MLA

Liaw, Yun-Fan. "Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.." Journal of gastroenterology and hepatology, 2004.

RethinkPeptides

RethinkPeptides Research Database. "Thymalfasin (thymosin-alpha 1) therapy in patients with chro..." RPEP-00941. Retrieved from https://rethinkpeptides.com/research/liaw-2004-thymalfasin-thymosinalpha-1-therapy

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.